Physician profile
Mark Stuart Jeffries
NPI 1568458040
$9,664.21
in general payments reported to CMS, 2019-2025
39 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,642 · 2020: $1,043 · 2021: $527 · 2022: $813 · 2023: $1,139 · 2024: $2,434 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,638.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,309.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,096.47 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,035.59 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $981.66 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $843.21 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $661.34 | 2019-2025 | |
| Antares Pharma, INC. | $413.06 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $401.92 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $342.79 | 2019-2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Amarin Pharma, INC. | $332.06 | 2019-2021 | |
| Allergan, INC. | $321.07 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $175.05 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.86 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $148.50 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $141.55 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jeffries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.